Medicine for combined use in cancer treatment
AssigneeSichuan Jiuzhang Biological Science and Technology Co., Ltd.
InventorsJie Zhang, Wang Huang, Huarong Yang
Life of this patent
Estimating the term…
Abstract
A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.
Claims3
A combined medicine for treating cancer, comprising chlorogenic acid and a hormone drug in a unit preparation comprising the same or different dosage forms, and a pharmaceutically acceptable carrier, wherein said hormone drug is selected from fulvestrant, abarelix, degarelix, and combinations thereof, chlorogenic acid is administrated at 10-40 mg/kg, fulvestrant is administrated at 40 mg/kg, abarelix is administrated at 15 mg/kg, and degarelix is administrated at 30 mg/kg, and said cancer is hormone-dependent breast, prostate, ovarian, and/or cervical cancer(s).
Dependencies are inferred from the claim text.